Going for diagnostic clout

By BC Staff | Jan 25, 1999 | 8:00 AM GMT

The planned merger between Shield Diagnostics Group plc (LSE:SDG) and Axis Biochemicals AS (OSE:AXI) will create a heart disease testing company valued at about £160 million ($264 million) with enhanced clout when it comes to dealing with multinational diagnostics distributors.

While both companies could have continued on their